The Effects Of Statin On Atrial Fibrillation:a Meta-analysis Of Published Data From Randomized Controlled Trials

Objective:We performed a meta-analysis of randomized trials with statin on the endpoint of incidence of AF to estimate the impact of statin use on AF development.Methods:We searched PubMed, EMbase, and the Cochrane controlled Trials Register (Cochrane Library Issue4,2010) until Novermber2010to identify studies covering the use of statins on atrial fibrillation. We performed the statistical calculations by RevMan, version4.2.10(The Cochrane Collaboration, Oxford, UK).Results:1. In published data from9short term trials, the effect of statins was significantly associated with a decreased risk of recurrence of AF (OR0.43,95%CI0.25to0.73, P=0.002).2. The result of OR was higher when studies with Jadad score<3were excluded (OR0.32,95%CI0.18to0.54, P<0.0001).3. Among4long term trials, the effect of statins was associated with a decreased risk of recurrence of AF (OR0.81,95%CI0.68to0.97, P=0.02).4. In3long term trials of more intensive versus standard statin, there was no evidence of a reduction in the risk of AF (OR1.05,95%CI0.79to1.40, P=0.74).Conclusion: 1. Our meta-analysis suggests that the use of statins may be associated with preventing AF in the short term trials and the long term trials.2. In the long term trials of more intensive versus standard statin, there was no evidence of a reduction in the risk of AF.3. We still need large-scale randomized double blind statin trails with AF occurrence as the main endpoint in order to finally confirm the benefits of statin in AF patients.